HealthcareWHO strongly recommends antiviral drug for patients with non-severe...

WHO strongly recommends antiviral drug for patients with non-severe COVID-19


patient
Credit: Unsplash/CC0 Public Domain

Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for patients with non-severe COVID-19 who are at highest risk of hospitalization, such as unvaccinated, older, or immunosuppressed patients, with lack of vaccination as an additional risk factor to consider, says a WHO Guideline Development Group of international experts in The BMJ today.

The experts explain that nirmatrelvir/ritonavir likely represents a superior choice for these patients because it may prevent more hospitalizations than the alternatives, has fewer potential harms than the antiviral drug molnupiravir, and is easier to administer than intravenous options such as remdesivir and antibody treatments.

However, they recommend against its use in patients at lower risk, as the benefits are trivial. And they make no recommendation for patients with severe or critical COVID-19, as there are currently no trial data on nirmatrelvir/ritonavir for this group.

Their recommendation is based on new data from two randomized controlled trials involving 3,100 patients.

In these trials, moderate certainty evidence showed that nirmatrelvir/ritonavir reduced hospital admission (84 fewer admissions per 1,000 patients), low certainty evidence suggested no important difference in mortality, and high certainty evidence suggested little or no risk of adverse effects leading to drug discontinuation.

In the same guideline update, WHO also makes a conditional (weak) recommendation to use the antiviral drug remdesivir for patients with non-severe COVID-19 at highest risk of hospitalization.

This is based on new data from five randomized controlled trials involving 2,700 patients and replaces a previous against treatment with remdesivir in all patients with COVID-19 regardless of disease severity.

The panel noted that should be administered as early as possible in the course of the disease, and acknowledged some cost and resource implications which may make access to low and challenging, noting, also, that the access to these drugs is tied to the access to SARS-CoV-2 , especially for those targeting the early phase of disease.

There also remains uncertainty regarding risk of emergence of resistance, they add.

Today’s recommendations are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide trustworthy guidance on the management of COVID-19 and help doctors make better decisions with their patients.

Living guidelines allow researchers to update previously vetted and peer reviewed evidence summaries as new information becomes available.

Today’s guidance adds to previous conditional recommendations for the use of molnupiravir for high-risk patients with non-severe COVID-19 and for the use of sotrovimab or casirivimab-imdevimab (monoclonal antibody treatments) in selected patients; and against the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with COVID-19 regardless of . For with severe COVID-19, WHO strongly recommends corticosteroids, with the addition of IL-6 receptor blockers or baricitinib.


WHO recommends antiviral drug for patients with non-severe COVID-19 at highest risk of hospital admission


More information:
Arnav Agarwal et al, A living WHO guideline on drugs for covid-19, BMJ (2020). DOI: 10.1136/bmj.m3379

Citation:
WHO strongly recommends antiviral drug for patients with non-severe COVID-19 (2022, April 21)
retrieved 22 April 2022
from https://medicalxpress.com/news/2022-04-strongly-antiviral-drug-patients-non-severe.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Original Source Link

Latest News

Microsoft, Khan Academy launch free AI assistant for all U.S. teachers

Microsoft is partnering with tutoring organization Khan Academy to provide a generative AI assistant to all teachers in...

Crypto insiders anxious and divided as spot Ether ETF decision date looms

Currently, betting markets indicate a 61% chance of U.S. spot Ether ETF approval, up from less than 11%...

Biden donors split over US response to Israel-Hamas war

This is an onsite version of the US Election Countdown newsletter. You can read the previous edition here. Sign...

A French AI startup, simply called H and founded by ex-Google DeepMind scientists, raised $220M from Accel and others, and plans a model capable...

Mark Bergen / Bloomberg: A French AI startup, simply called H and founded by ex-Google DeepMind scientists, raised...

Jon Stewart, “Trump Is The Real Cancel Culture.”

Jon Stewart called out the right’s fake cancel culture and pointed out that the one real source of...

Must Read

- Advertisement -

You might also likeRELATED
Recommended to you